WO2007106708A3 - Combinaison de composes organiques - Google Patents

Combinaison de composes organiques Download PDF

Info

Publication number
WO2007106708A3
WO2007106708A3 PCT/US2007/063553 US2007063553W WO2007106708A3 WO 2007106708 A3 WO2007106708 A3 WO 2007106708A3 US 2007063553 W US2007063553 W US 2007063553W WO 2007106708 A3 WO2007106708 A3 WO 2007106708A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic
disease
renal
pharmaceutically acceptable
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/063553
Other languages
English (en)
Other versions
WO2007106708A2 (fr
Inventor
Yasser Khder
Gary Michael Ksander
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007106708A2 publication Critical patent/WO2007106708A2/fr
Publication of WO2007106708A3 publication Critical patent/WO2007106708A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'agents thérapeutiques, ladite combinaison consistant en (i) du valsartan antagoniste d'AT-1 ou sel dérivé pharmaceutiquement acceptable, optionnellement en présence d'un diurétique et (ii) un acide acétique inhibiteur NEP (3S,2'R)-3-{1-[2'-(éthoxycarbonyl)-4'-phényl-butyl]-cyclopentan-1-carbonylamino}-2,3,4,5-tétrahydro-2-oxo-1H-1-benzazépine-1 ou sel dérivé pharmaceutiquement acceptable et optionnellement un support pharmaceutiquement acceptable; elle concerne aussi un procédé de traitement ou de prévention d'une condition ou d'une maladie sélectionnée dans un groupe comportant l'hypertension ou une insuffisance cardiaque telle qu'une insuffisance cardiaque congestive (aiguë ou chronique), un dysfonctionnement ventriculaire gauche et une cardiomyopathie hypertrophique, une myopathie cardiaque diabétique, des arrhytmies supraventriculaires et ventriculaires, une fibrillation ou un flutter auriculaire, un remodelage vasculaire nuisible, un infarctus myocardique et ses séquelles, une athérosclérose, une angine, (qu'elle soit instable ou stable), une insuffisance rénale (diabétique et non diabétique), une insuffisance cardiaque, une angine de poitrine, un diabète, un aldostéronisme secondaire, une hypertension pulmonaire primaire et secondaire, des conditions d'insuffisance rénale, telles qu'une néphropathie diabétique, une glomérulonéphrite, une sclérodermie, une sclérose glomérulaire, une protéinurie de maladie rénale primaire et aussi, une hypertension vasculaire rénale, une rétinopathie diabétique, la gestion d'autres troubles vasculaires tels qu'une migraine, une maladie vasculaire périphérique, la maladie de Raynaud, l'hyperplasie luminale, un dysfonctionnement cognitif (tel que la maladie d'Alzheimer), le glaucome et un infarctus, y compris l'administration à un mammifère qui en a besoin d'une quantité thérapeutiquement effective de la composition pharmaceutique.
PCT/US2007/063553 2006-03-10 2007-03-08 Combinaison de composes organiques Ceased WO2007106708A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78116806P 2006-03-10 2006-03-10
US60/781,168 2006-03-10

Publications (2)

Publication Number Publication Date
WO2007106708A2 WO2007106708A2 (fr) 2007-09-20
WO2007106708A3 true WO2007106708A3 (fr) 2007-12-27

Family

ID=38508805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/063553 Ceased WO2007106708A2 (fr) 2006-03-10 2007-03-08 Combinaison de composes organiques

Country Status (1)

Country Link
WO (1) WO2007106708A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
JP2011506459A (ja) 2007-12-11 2011-03-03 セラヴァンス， インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
EP2297113A1 (fr) 2008-04-29 2011-03-23 Theravance, Inc. Agents antihypertenseurs à double action
WO2010011821A2 (fr) 2008-07-24 2010-01-28 Theravance, Inc. Agents anti-hypertensifs à double action
EP2451782B1 (fr) 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Agent antihypertenseurs pyrazoles à double action
JP2012533626A (ja) 2009-07-22 2012-12-27 セラヴァンス， インコーポレーテッド 二重作用オキサゾール降圧剤
WO2011090929A1 (fr) 2010-01-19 2011-07-28 Theravance, Inc. Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
BR112013011715A2 (pt) 2010-11-10 2017-10-31 Theravance Inc formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil
US8586536B2 (en) 2010-12-15 2013-11-19 Theravance, Inc. Neprilysin inhibitors
ES2548887T3 (es) 2010-12-15 2015-10-21 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
KR101854874B1 (ko) 2011-02-17 2018-05-04 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 억제제로서 치환된 아미노부티릭 유도체
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
ES2653215T3 (es) 2011-05-31 2018-02-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
WO2012166389A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de néprilysine
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
TW201336839A (zh) 2012-02-15 2013-09-16 Theravance Inc （２ｓ，４ｒ）－５－聯苯－４－基－２－羥甲基－２－甲基－４－［（１ｈ－［１，２，３］三唑－４－羰基）－胺基］－戊酸５－甲基－２－酮基－［１，３］二氧雜環戊烯－４－基甲酯之結晶型
WO2013148768A1 (fr) 2012-03-28 2013-10-03 Theravance, Inc. Formes cristallines de l'ester isopropylique de l'acide (r)-3-[n-(3'-chlorobiphényl-4-ylméthyl)-n'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionique
ES2609810T3 (es) 2012-05-31 2017-04-24 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina donadores de óxido nítrico
CN104470521B (zh) 2012-06-08 2017-04-12 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
MX356260B (es) 2012-06-08 2018-05-21 Theravance Biopharma R&D Ip Llc Inhibidores de la neprilisina.
MX366149B (es) 2012-08-08 2019-06-28 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
CA2902456A1 (fr) 2013-03-05 2014-09-12 Theravance Biopharma R&D Ip, Llc Inhibiteurs de la neprilysine
US9585882B2 (en) 2014-01-30 2017-03-07 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
WO2015116786A1 (fr) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Inhibiteurs de la néprilysine
KR102640906B1 (ko) 2015-02-11 2024-02-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
CN107250119B (zh) 2015-02-19 2020-09-22 施万生物制药研发Ip有限责任公司 (2r,4r)-5-(5′-氯-2′-氟联苯-4-基)-2-羟基-4-[(5-甲基恶唑-2-羰基)氨基]戊酸
SMT202100434T1 (it) 2016-03-08 2021-09-14 Theravance Biopharma R&D Ip Llc Acido (2s,4r)-5-(5’-cloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etossimetil)-4-(3-idrossiisossazol-5-carbossammido)-2-metilpentanoico cristallino e suoi usi
EP3248592A1 (fr) 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Procédé pour la préparation de systèmes d'administration de médicament comprenant un composé de testostérone présent dans une couche ou une partie externe, ainsi que de tels systèmes d'administration de médicaments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A2 (fr) * 1991-02-06 1992-08-12 Schering Corporation Association d'un antagoniste de l'angiotensine-II ou d'un inhibiteur de la rénine avec un inhibiteur de l'endopeptidase neutre
WO2003059345A1 (fr) * 2002-01-17 2003-07-24 Novartis Ag Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
WO2006000564A1 (fr) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1
WO2007056546A1 (fr) * 2005-11-09 2007-05-18 Novartis Ag Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
WO2007054975A1 (fr) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A2 (fr) * 1991-02-06 1992-08-12 Schering Corporation Association d'un antagoniste de l'angiotensine-II ou d'un inhibiteur de la rénine avec un inhibiteur de l'endopeptidase neutre
WO2003059345A1 (fr) * 2002-01-17 2003-07-24 Novartis Ag Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
WO2006000564A1 (fr) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs de l'epn, inhibiteurs du systeme de production de l'endotheline endogene et antagonistes du recepteur at1
WO2007054975A1 (fr) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
WO2007056546A1 (fr) * 2005-11-09 2007-05-18 Novartis Ag Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep

Also Published As

Publication number Publication date
WO2007106708A2 (fr) 2007-09-20

Similar Documents

Publication Publication Date Title
WO2007106708A3 (fr) Combinaison de composes organiques
AU2003206738C1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors
LU92000I2 (fr) Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables
EP2322174A3 (fr) Utilisation combinée de valsartane et bloqueurs du canal de calcium à but thérapeutique
WO2007045663A3 (fr) Combinaison de composes organiques
AR040017A1 (es) Combinacion de compuestos organicos
BR0317384A (pt) Combinações de valsartan com inibidores de cox-2

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07758135

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07758135

Country of ref document: EP

Kind code of ref document: A2